These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39074980)

  • 1. Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine.
    Barrow A; Cohen C; Serpico J; Goodman M; Grossman D; Raifman S; Upadhyay U
    Perspect Sex Reprod Health; 2024 Jul; ():. PubMed ID: 39074980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amicus brief of over 300 reproductive health researchers supports mifepristone's safety and effectiveness.
    Barrow A; Cohen C; Serpico J; Goodman M; Grossman D; Raifman S; Upadhyay U
    Perspect Sex Reprod Health; 2024 Jul; ():. PubMed ID: 39074978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mifepristone Litigation: Untangling the Implications of the Fifth Circuit's Decision for Abortion Access and the U.S. Food and Drug Administration.
    Zettler PJ; Grossman LA; Adashi EY; Cohen IG
    Ann Intern Med; 2023 Dec; 176(12):1666-1669. PubMed ID: 37931255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA preemption of conflicting state drug regulation and the looming battle over abortion medications.
    Grossi P; O'Connor D
    J Law Biosci; 2023; 10(1):lsad005. PubMed ID: 36938304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.
    Razon N; Wulf S; Perez C; McNeil S; Maldonado L; Fields AB; Carvajal D; Logan R; Dehlendorf C
    Contraception; 2022 May; 109():19-24. PubMed ID: 35131289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mifepristone REMS: A needless and unlawful barrier to care✰.
    Kaye J; Reeves R; Chaiten L
    Contraception; 2021 Jul; 104(1):12-15. PubMed ID: 33930383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Impacts of the Supreme Court Case FDA v Alliance for Hippocratic Medicine.
    Espey E; Hailstorks T; Hofler L
    JAMA; 2024 May; 331(18):1529-1530. PubMed ID: 38526871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration v Alliance for Hippocratic Medicine-A Cautious Win for Reproductive Health Care and FDA Authority.
    Goodwin MB; Whelan AM; Gostin LO
    JAMA; 2024 Aug; 332(6):453-454. PubMed ID: 38913506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benten v. Kessler: the RU 486 import case.
    Pine RN
    Law Med Health Care; 1992; 20(3):238-42. PubMed ID: 1434768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abortion exceptionalism and the mifepristone REMS.
    Serpico JJ
    Contraception; 2021 Jul; 104(1):8-11. PubMed ID: 33831445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remote Reproductive Rights.
    Rebouché R
    Am J Law Med; 2022 Jul; 48(2-3):244-255. PubMed ID: 36715252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.
    Srinivasulu S; Yavari R; Brubaker L; Riker L; Prine L; Rubin SE
    Contraception; 2021 Jul; 104(1):92-97. PubMed ID: 33910031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supreme Court refuses to review clinic access law; Second Appeals Court upholds statute.
    Reprod Freedom News; 1995 Jun; 4(13):2-3. PubMed ID: 12346292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggested FDA restrictions might curtail access to mifepristone.
    Contracept Technol Update; 2000 Aug; 21(8):89-91. PubMed ID: 12349758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deception by obfuscation: Studnicki et al.'s retracted longitudinal cohort study of emergency room utilization following abortion.
    Upadhyay UD; Adkins CE
    Contraception; 2024 Jun; 134():110417. PubMed ID: 38494149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief of Amici Curiae economists in support of respondents in Dobbs v. Jackson Women's Health Organization.
    Myers C; Srinivasan A
    Perspect Sex Reprod Health; 2024 May; ():. PubMed ID: 38745396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RU-486: legal and policy issues confronting the Food and Drug Administration.
    Muhl C
    J Leg Med; 1993 Jun; 14(2):319-47. PubMed ID: 8340714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacists' experiences dispensing misoprostol and readiness to dispense mifepristone.
    Ferketa M; Moore A; Klein-Barton J; Stulberg D; Hasselbacher L
    J Am Pharm Assoc (2003); 2024; 64(1):245-252.e1. PubMed ID: 37913990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Supreme Court's Abortion Exceptionalism - Judicial Deference, Medical Science, and Mifepristone Access.
    Fox D; Cole E
    N Engl J Med; 2021 Jun; 384(24):e94. PubMed ID: 33909959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.